Therapeutic anti CD3 monoclonal antibodies: from bench to bedside.
The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.
Immunotherapy